To date only 6 additional markers have been approved by the FDA under the category of tumor associated antigens: CA 19-9 in May of 2002, Her2/Neu in September of 2000, CA 15.3 in February of 1981, bladder tumor marker in April of 1997, thyroglobulin in March of 1999 and CA 125 in July of 1987 (Table 4). The gene discussed is TG; the disease is urinary bladder neoplasm.